An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial

References

• From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2020. Available from: http://goldcopd.org/. Accessed May 6, 2021.
   Google Scholar
• Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Ferrer M, Pont À, et al.; IMPAC Study Group. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax. 2004;59:387–395. doi:10.1136/thx.2003.008730
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131:20–28. doi:10.1378/chest.06-1316
   PubMed Web of Science ®Google Scholar
• Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev. 2005;14:32–38. doi:10.1183/09058180.05.00009404
   Google Scholar
• Hunter MH, King DE. COPD: management of acute exacerbations and chronic stable disease. Am Fam Physician. 2001;64:603–613.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;16:1608–1613. doi:10.1164/ajrccm.161.5.9908022
   Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha J. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179:369–374. doi:10.1164/rccm.200807-1067OC
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–635.
   PubMed Web of Science ®Google Scholar
• Down K, Amour A, Baldwin IR, et al. Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease. J Med Chem. 2015;58(18):7381–7399. doi:10.1021/acs.jmedchem.5b00767
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77. doi:10.1016/j.pupt.2017.08.008
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134(2):314–322. doi:10.1016/j.jaci.2014.02.001
   PubMed Web of Science ®Google Scholar
• To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:897–904. doi:10.1164/rccm.200906-0937OC
   PubMed Web of Science ®Google Scholar
• Angulo I, Vadas O, Garçon F, et al. Phosphoinositide 3-kinase gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866–871. doi:10.1126/science.1243292
   PubMed Web of Science ®Google Scholar
• Stark AK, Chandra A, Chakraborty K, et al. PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun. 2018;9:3174. doi:10.1038/s41467-018-05674-8
   PubMed Web of Science ®Google Scholar
• Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97. doi:10.1038/ni.2771
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. AM J Respir Crit Care Med. 2011;183:1176–1186. doi:10.1164/rccm.201008-1285OC
   PubMed Web of Science ®Google Scholar
• Stark A-K, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82–91.
   PubMed Web of Science ®Google Scholar
• Rangelov BA, Young AL, Jacob J, et al. Thoracic imaging at exacerbation of chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis. 2020;15:1751–1787. doi:10.2147/COPD.S250746
   PubMed Web of Science ®Google Scholar
• Vos W, Van Holsbeke C, Van Geffen W, et al. Changes in functional respiratory imaging (FRI) endpoints correlate with changes in patient reported outcomes (PRO) after recovering from acute COPD exacerbation. Eur Respir J. 2015;46(suppl 59):OA2948.
   Google Scholar
• Vos W, Van Holsbeke C, De Backer J, De Backer WA. Correlation between changes in FEV1 and functional respiratory imaging biomarkers in a large population of asthma and COPD patients. Am J Respir Crit Care Med. 2015;191:A2266.
   Web of Science ®Google Scholar
• De Backer LA, Vos WG, Salgado R, et al. Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:637–646. doi:10.2147/COPD.S21917
   PubMed Web of Science ®Google Scholar
• Lanclus M, Clukers J, Van Holsbeke C, et al. Machine learning algorithms utilizing functional respiratory imaging may predict COPD exacerbations. Acad Radiol. 2019;26:1191–1199. doi:10.1016/j.acra.2018.10.022
   PubMedGoogle Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for steel and coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;6(suppl 16):5–40. doi:10.1183/09041950.005s1693
   Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586. doi:10.1136/thx.54.7.581
   PubMed Web of Science ®Google Scholar
• van Geffen WH, Hajian B, Vos W, et al. Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1783–1792. doi:10.2147/COPD.S152463
   PubMed Web of Science ®Google Scholar
• Barbosa E, Ferreira F, Vos W, et al. Quantitative functional respiratory imaging may predict the mechanism of FEV1 decline after lung transplantation. Eur Respir J. 2017;50:PA2465.
   Web of Science ®Google Scholar
• Vos W, Janssens A, Van Holsbeke C, et al. Functional respiratory imaging to predict post-operative FEV1 after lobectomy/pneumonectomy. Eur Respir J. 2014;44:P342. doi:10.1183/09031936.00011714
   Web of Science ®Google Scholar
• Lins M, Vandevenne J, Thillai M, et al. Assessment of small pulmonary blood vessels in COVID-19 patients using HRCT. Acad Radiol. 2020;27:1449–1455. doi:10.1016/j.acra.2020.07.019
   PubMed Web of Science ®Google Scholar
• Thillai M, Patvardhan C, Swietlik EM, et al. Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19. Thorax. 2020. doi:10.1136/thoraxjnl-2020-215395
   Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Magnussen H, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19:251–266. doi:10.1186/s12931-018-0944-3
   PubMed Web of Science ®Google Scholar
• Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–2786. doi:10.3109/10428194.2015.1022770
   PubMed Web of Science ®Google Scholar
• Sánchez-Alegría K, Flores-León M, Avila-Muñoz E, Rodríguez-Corona N, Arias C. PI3K Signaling in neurons: a central node for the control of multiple functions. Int J Mol Sci. 2018;19:3725. doi:10.3390/ijms19123725
   PubMed Web of Science ®Google Scholar
• Wilson R, Cahn A, Montembault M, et al. Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers. Eur Respir J. 2014;44(Suppl 58):3411.
   Google Scholar